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A matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry-based genotyping assay,
termed restriction fragment mass polymorphism (RFMP)
has been recently developed for detecting hepatitis B
virus (HBV) mutants. The assay is based on PCR amplifi-
cation and mass measurement of oligonucleotides
containing sites of mutations that confer resistance to
lamivudine. We compared the efficacy and usefulness of
the RFMP assay with a commercial assay using a reverse
hybridization line probe technology, namely INNO-LiPA
HBV DR (referred to henceforth as the LiPA assay), for the
detection of lamivudine-resistant HBV mutants. A total
of 60 patient samples were analysed for the presence of
mutations at rtL180M and rtM204I/V of HBV polymerase
by the LiPA and RFMP assays. The ability to detect muta-
tions at rtM204I/V was compared with defined mixtures
of wild-type and mutant HBV cloned in plasmids at rela-
tive concentrations ranging from 1–25%. Concordance
between methods was found to be 95.0% (57/60) when
only the presence of resistance mutations was consid-
ered, regardless of quasispecies. In three cases, additional
minor populations of resistant viruses were identified by
RFMP. Defined mixtures were consistently successfully
identified at a 1% relative concentration of mutant
versus wild-type viruses by the RFMP assay and 4% by
the LiPA assay. The RFMP assay proved to be an accurate
and reliable tool for detection of lamivudine-resistant
mutations and was more sensitive than the LiPA assay in
detecting mixtures of mutant and wild-type viruses. The
improved sensitivity of the RPMP assay can help monitor
drug resistance as it develops, enabling early intervention
and prevention.
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Chronic infection with hepatitis B virus (HBV) is a
leading cause of cirrhosis and hepatocellular carcinoma
and, in addition to morbidity and mortality, creates
significant economic and social burdens [1].
Worldwide, approximately 400 million people have
chronic hepatitis B infection, of whom 15–40% can be
expected to develop serious hepatic complications [2].
Although both the spread of HBV infection and the
development of hepatocellular carcinoma can be effec-
tively checked by vaccination, treatment with antivirals
remains the only therapeutic option available to chron-
ically infected patients [3].
The objective of treating chronic HBV infection is to
halt progression of liver injury by suppressing viral
replication and infection [4]. The availability of lamivu-
dine [(–)-β-L-2′,3′-dideoxy-3′-thiacytidine; 3TC] has
revolutionized the treatment of chronic hepatitis B and
made new options available for the management of
patients with decompensated cirrhosis or recurrent
hepatitis B, post liver transplantation [5]. Unfortunately,
long-term lamivudine therapy promotes the selection of
HBV mutants with altered DNA polymerases resistant
to therapy. The altered DNA polymerases frequently
exhibit changes in a highly conserved tyrosine, methio-
nine, aspartate and aspartate (YMDD) motif, and so are
named YMDD mutants. The most commonly described
mutations are the substitution of valine or isoleucine for
methionine at residue 204 (rtL204I/V) with or without
the rtL180M mutation [6–8].
The incidence of YMDD mutants is increasing at a
rate of 15–20% per year and correlates with higher pre-
therapeutic viral load, histological activity scores and
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alanine aminotransferase (ALT) levels before therapy
[9]. Recent studies have shown that acute exacerba-
tions occur frequently and, in patients with lamivudine-
resistant mutants during long-term lamivudine
treatment, hepatic decompensation may develop,
which can be life-threatening [10,11]. An additional
concern is that individuals infected by HBV YMDD
mutants pre-transplant may have an increased risk of
recurrent infection post-transplant, with reappearance
of high levels of serum HBV [12,13]. Advances in
antiviral therapy, such as lamivudine, have brought
about an increasing need for sensitive and early detec-
tion of emerging drug-resistant mutants to monitor
drug resistance as it develops and aid early intervention
[14–19]. The identification of such mutations is of
increasing importance, especially as alternative antivi-
rals such as adefovir and entecavir, which are effective
against lamivudine-resistant HBV, have become avail-
able [20,21].
We have recently developed a matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF MS)-based genotyping assay, termed
restriction fragment mass polymorphism (RFMP),
which exploits differences between YMDD wild-type
and variant sequences [22]. This assay represents an
improvement over gel-based assays because it relies
upon precise information about the molecular mass of
the analyte, both DNA strands can be analysed in
parallel and it can be fully automated. In this study, we
established a RFMP assay for rtL180M in addition to
rtM204I/V and compared the results of the RFMP
assay with those of the INNO-LiPA HBV DR line
probe assay (hereafter referred to as the LiPA assay).
The concordance and ability to identify mixed wild-
type and mutant viral populations of the two methods
were assessed in this evaluation.
Materials and methods
Specimens
Sera were collected from 60 hepatitis B patients who
were predicted to develop viral breakthrough, defined
as rebound of viral load, during lamivudine treatment
at the Liver Clinic of Yonsei University Medical Centre
in Seoul, Republic of Korea, between December 2003
and April 2004. All of the serum samples were deter-
mined to have genotype C by the LiPA assay. None of
the patients was positive for either anti-hepatitis C
virus antibody or anti-HIV antibody. Experimental
protocol conformed to the ethical guidelines of the
1975 Declaration of Helsinki as reflected in a priori
approval by Yonsei University Medical Centre human
research committee. Hepatitis B surface antigen and
hepatitis B e antigen/antibody were determined by
enzyme immunoassay (Abbott Diagnostics, Chicago,
IL, USA). HBV DNA was measured by the Digene
hybrid capture assay (Digene Diagnostics,
Gaithersburg, MD, USA) with a lower limit of
0.5 pg/ml. HBV DNA was extracted from 200 µl of
serum using the High Pure PCR Template Kit (Roche
Diagnostics Corp, Indianapolis, IN, USA) according to
the manufacturer’s instructions; 2 µl of the viral DNA
was used for the PCR reaction.
INNO-LiPA HBV DR line probe assay
This LiPA assay uses genotype-specific oligonucleotide
probes attached to nitrocellulose strips to detect
sequence variants located at amino acid positions 180,
204 and 207 in HBV polymerase [23]. The biotin-
labelled PCR product was hybridized to the probes on
the strip under stringent conditions. After hybridiza-
tion and washing, streptavidin-labelled alkaline phos-
phatase was added, followed by incubation with a
chromogen, which results in the development of a
purple-brown precipitate when there is a match
between the probe and the biotinylated PCR product.
The test was performed according to the manufac-
turer’s instructions (Innogenetics NV, Ghent, Belgium).
A proficiency panel was tested to demonstrate
adequate experience with the technique. Results were
blinded until all tests were completed and taken for
further analysis only when identical results were
obtained from two independent experiments.
RFMP genotyping
PCR was performed in 18 µl of reaction mixture
containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl,
0.2 mM of each dNTP, 10 pmol of each primer and
0.4 units of Platinum® Taq DNA polymerase (Invitrogen,
Carlsbad, CA, USA). The amplification conditions
included initial denaturation at 94˚C for 2 min, 10
cycles of denaturation at 94˚C for 15 s, annealing at
50˚C for 15 s and extension at 72˚C for 30 s, followed
by 35 cycles of denaturation at 94˚C for 15 s, annealing
at 55˚C for 15 s and extension at 72˚C for 30 s. The
sequences of forward and reverse primers used in the
PCR are described in Table 1. Restriction enzyme diges-
tion of PCR products was performed by mixing the
PCR reaction mixture with 10 µl of buffer containing
50 mM potassium acetate, 20 mM Tris-acetate, 10 mM
magnesium acetate, 1 mM dithiothreitol and 1 unit of
FokI. The reaction mixture was incubated at 37˚C for
2 h and further incubated at 45˚C for 2 h with BstF5I.
The resulting digest was desalted by vacuum filtration
through a 384-well sample preparation plate
containing 5 mg of polymeric sorbent (Waters,
Miliford, MA, USA) per well. Each well was equili-
brated with 90 µl of 1 M triethylammonium acetate
(TEAA, pH 7.6). Each cleavage reaction mixture was
added to 70 µl of 1 M TEAA (pH 7.6) and loaded into
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a well. After rinsing five times with 85 µl of 0.1 M
TEAA pH 7.0, the plate was reassembled on a vacuum
manifold and eluted with 60 µl of 60% aqueous
isopropanol into a collection plate, which was placed
on a heating block at 115˚C for 90 min. The desalted
reaction mixtures were resuspended with matrix solu-
tion containing 50 mg/ml 3-hydroxy picolinic acid
(Sigma, Saint Louis, MO, USA), 0.05 M ammonium
citrate (Sigma) and 30% acetonitrile (Sigma), and were
spotted in 3 µl volumes on a polished anchorchip plate.
Mass spectra were acquired on a linear MALDI-TOF
MS (Bruker Daltonics Biflex IV, Billerica, MA, USA)
workstation in a positive ion, delayed extraction mode.
Typically, time-of-flight data from 20–50 individual
laser pulses were recorded and averaged on a transient
digitizer, after which the averaged spectra were auto-
matically converted to mass by data processing soft-
ware (Bruker DataAnalysis for TOF 1.6m).
Validation of genotyping by clonal sequencing
To amplify the HBV polymerase gene encoding the
YMDD motif for cloning and sequencing, PCR was
performed with a primer pair BF111 and BF109 as
described by Chayama et al. [24]. The PCR products
were cloned into the pCR-Script Amp cloning vector
(Stratagene, La Jolla, CA, USA) and subsequently
sequenced with vector-specific primers. Twenty clones
were initially sequenced for each sample; additional
clones were sequenced when the presence of a mixed
population could not be demonstrated. Sequence
analysis was performed by ABI PRISM 310 Genetic
Analyzer (Applied Biosystems, New York, NY, USA).
Results
RFMP genotyping strategy
The RFMP assay is based on mass spectrometric analysis
of small DNA fragments containing sites of variation
(Figure 1). The first step requires PCR amplification
using primers flanking the altered bases. The forward
primer was designed to introduce a FokI site (an
isoschizomer of BstF5I) in the amplified product by
substituting the restriction recognition sequence
GGATG for one nucleotide present within eight bases
away from the mutated site. The reverse primer was
designed to make the resulting amplicon as short as
possible while both primers’ Tm values matched with
each other for better PCR yield. Both FokI and BstF5I
are type IIS restriction enzymes that cleave DNA
outside the recognition sequence. The FokI enzyme
cleaves DNA nine bases 3′ to the recognition site on one
strand and 13 bases from the recognition site on the
other strand, leaving a four-base overhanging,
protruding 5′ end. BstF5I cleaves DNA two bases 3′ to
the recognition site on one strand and immediately 3′ to
the recognition site on the opposite strand, leaving a
two-base overhang. As summarized in Table 2, the 7-
mer fragments contain the polymorphic bases at the
first bases of codon 180 or 204, and the 13-mer frag-
ments contain the three bases of codon 180 and 204
and two additional bases from the HBV sequences.
These fragments were then analysed by mass spectrom-
etry to identify the mutations at codon 180 and 204.
Concordance between RFMP and LiPA assays
Both genotyping methods were able to genotype all the
samples enrolled (60/60). Identical results were found
in 56 of the 60 samples (93.3%). In four samples, there
were discrepancies observed between the results of the
two assays, as presented in Figure 2. In all of these
cases, RFMP indicated the presence of additional virus
species (Table 3). In three cases (5.0%), RFMP revealed
the presence of both mutant and wild-type viruses,
while LiPA detected only wild-type virus. LiPA detected
the mutant virus in specimens taken from these patients
at a later time point, indicating that the mutant virus
was already present in the previous sample and that
RFMP detected it before LiPA did. In another sample,
RFMP exhibited mixed rtM204I and rtM204V
mutants along with wild-type while LiPA identified
only the rtM204I mutant co-existing with wild-type
virus. Existence of the additional viral species shown in
RFMP was further verified by the clonal analysis using
direct sequencing of multiple clones representing PCR
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Table 1. Primers used in amplification for RFMP assays of rtM204V/I and rtL180M
Primer Sequences (5′–3′) Position Polarity
rfmp204f TTCCCCCACTGTTTGGCTggatgTCAGTTAT 712–738 Sense
rfmp204r TACAGACTTGGCCCCCAATACCACATGA 771–744 Antisense
rfmp180f ATTCCTATGGGAGTGGGCCTCAGTggatgCGTTTCTC 634–666 Sense
rfmp180r ACGAACCACTGAACAAATGGCACTAGTAAACTG 705–673 Antisense
Primers were designed based on the consensus sequences extracted from the multiple alignment of HBV sequences retrieved from the Entrez Nucleotide database of
the National Center for Biotechnology Information, Bethesda, MD, USA and detailed information is available upon request. A five-nucleotide sequence (ggatg)
embedded in the forward primer to introduce a FokI site in amplicon is indicated by lower case letters. A single base mismatch (underlined G) was introduced to
erase the naturally occurring FokI site (nucleotides 741–745). Nucleotide sequence positions were numbered according to Ono et al. [34].
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Figure 1. RFMP strategy
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PCR was performed with primers containing a type IIS restriction endonuclease recognition sequence (GGATG; FokI) embedded nine bases ahead of rtL180 and
rtM204. The enzymatic digestion of the products released a pair of 7-mer and 13-mer fragments representing nucleotide sequences within the codons shown in bold
italic, and then masses of the resulting oligonucleotide fragments were analysed by the mass spectrometer. Cleavage sites of FokI and BstF5I, an isoschizomer for
FokI, are indicated by black and white triangles, respectively, and restriction endonuclease recognition sites and primers are indicated by shaded bars and shaded
arrows, respectively. One-base gaps (C at position 658 and T at position 720) replaced by the artificial sequences are denoted by blank spaces.
Table 2. Expected and observed masses of oligonucleotides resulting from restriction enzyme digestion of PCR products
Expected fragments (5′–3′)* Expected mass, Da Observed mass, Da
Sequence Amino acid 7-mer 13-mer 7-mer 13-mer 7-mer 13-mer
Codon 204
aTg Met AGTTATa TCcAtATAACTGA 2199.4 3997.6 2199.6 3998.0
gTg Val AGTTATg TCcAcATAACTGA 2215.4 3982.6 2215.9 3982.9
aTt Ile AGTTATa TCaAtATAACTGA 2199.4 4021.6 2199.6 4021.8
aTc Ile AGTTATa TCgAtATAACTGA 2199.4 4037.6 2199.6 4037.6
aTa Ile AGTTATa TCtAtATAACTGA 2199.4 4012.6 2199.6 4012.6
Codon 180
cTg Leu TTTCTCc GCcAgGAGAAACG 2102.4 4097.6 2102.6 4098.0
cTt Leu TTTCTCc GCaAgGAGAAACG 2102.4 4121.6 2102.6 4122.0
tTg Leu TTTCTCt GCcAaGAGAAACG 2117.4 4081.6 2117.8 4081.8
aTg Met TTTCTCa GCcAtGAGAAACG 2126.4 4072.6 2126.6 4073.0
*The first and third bases of codons 204 and 180 are shown in lower case letters.
products spanning sequences encoding the YMDD
motif. Overall, RFMP had 95.0% agreement with LiPA
when only the detection of mutant virus was consid-
ered, regardless of viral species.
Ability to detect mixed infection
To compare the ability to distinguish wild-type and
mutant DNA in mixed populations, the samples
composed of defined ratios of wild-type and mutant
sequences (nucleotide 411–886) in plasmids were
analysed by both the RFMP and LiPA methods. The
plasmids containing the nucleotide sequence of the
rtM204I or rtM204V mutants were diluted in known
negative HBV DNA serum to make concentrations
corresponding to 107 and 104 HBV genomic equiva-
lents/ml, respectively. The dilution series were made at
both DNA loads in a background of wild-type HBV
DNA in the following ratios: 25, 10, 4, 1 and 0%. As
shown in Figure 3, RFMP could detect 1% mutant
virus DNA, in agreement with previous reports [22].
Results were identical at both viral DNA concentra-
tions irrespective of mutant types. In contrast, the LiPA
assay could not detect the mutant DNA mixed with a
25-fold greater amount of wild-type DNA species, even
though the sample contained 107 copies of mutant plas-
mids. Thus, RFMP is more sensitive than LiPA in iden-
tifying a minor population of mutant virus DNA in a
background of wild-type virus.
Antiviral Therapy 10:3 445
Diagnostic methods for 3TC resistance in chronic hepatitis B
Figure 2. Samples showing discordant results between RFMP and LiPA
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Serum was taken from hepatitis B patients who showed rebound of viral load during lamivudine therapy and was subject to testing for lamivudine-resistant muta-
tions by RFMP and LiPA assays. RFMP detected lamivudine-resistant mutations in all samples, whereas LiPA only showed the mutations in one sample (strip 3). Mass
peaks indicating the presence of additional mutant virus in the RFMP results are underlined. The old nomenclature, L528M and M552V/I, was used in the reference
LiPA strip instead of rtL180M and rt204V/I. amp., amplification; conj., conjugate; m/z, mass-to-charge ratio; RI, relative peak intensity.
1 32
LiPA
Marker line
1 - Conj. control
2 - Amp. control
L528
M528
M5529 -
3 - 
4 - 
5 - 
6 - 
7 - 
8 - 
I552
10 -
11 -
12 -
13 -
14 -
15 -
V552
16 -
17 -
18 -
19 -
V555
L555
M555
20 -
21 - I555
Discussion
Lamivudine is currently considered a primary thera-
peutic option for patients affected with chronic hepatitis
B, irrespective of hepatitis e antigen status. Although the
initial response to the therapy is favourable in the
majority of patients, long-term response rates are chall-
enged by the selection and build-up of HBV with muta-
tions conferring drug resistance. Particularly for
patients at high risk for disease progression, it is impor-
tant to detect these mutants early and precisely during
the emergence of viral resistance when viral load in the
patient is very low and/or when mutant viruses repre-
sent only a minor fraction of the total viral population.
The performance of the RFMP assay for detecting
mutations associated with lamivudine resistance was
compared with that of LiPA for 60 chronically HBV-
infected patients who had shown viral DNA rebound in
serum during lamivudine treatment. The results demon-
strated a high level of concordance between the two
methods. Discordant results observed in four samples
could be attributed to the presence of additional virus
species detected only by RFMP. This is probably due to
the presence of minor viral subspecies that were missed
by LiPA, which usually only allows the detection of
minor virus mutants if they constitute about 10% of the
viral population [25]. The hypothesis was confirmed by
clonal analysis of the four samples, which revealed a
mixture of virus populations with mutant genotype,
and the analysis of a defined dilution series of wild-type
and mutant DNA, which indicated a lower detection
limit of 1% for RFMP. These results were of particular
interest because they indicated that the RFMP assay
can detect a mixed wild-type and mutant virus popula-
tion earlier than LiPA during therapy, and can monitor
a disappearing virus population for a longer time
period after cessation of lamivudine treatment. Thus,
the greater sensitivity of RFMP should be useful for
detecting lamivudine-resistant mutants and for moni-
toring drug resistance as it develops, enabling early
intervention and prevention.
At the onset of viral breakthrough, lamivudine-
resistant mutations were identified in 46 (76.7%) of the
60 patients (Table 3). In agreement with previous
reports [14], rtM204I is commonly found in lamivu-
dine-resistant subjects, being present either alone or
together with the rtL180M mutation. The significance
of virological breakthrough due to HBV strains
without mutations in the YMDD motif remains
unclear. Such breakthroughs were observed in 14 of
our 60 patients (23.3%). Recently, Papatheodordis et
al. reported that YMDD variants were absent in two
out of 32 patients with virological breakthrough; these
individuals remained with fluctuating low viraemia and
in biochemical remission during the following few
months [26]. It has been reported that approximately
5–20% of patients with HBV breakthrough showed no
detectable YMDD mutants; a possible explanation for
this observation has been attributed to partial or non-
responders to lamivudine, treatment non-compliance
or the emergence of other mutations (such as rtA181T)
H-S Kim et al.
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Table 3. Comparison of the results obtained by RFMP and LiPA analyses for 60 clinical specimens
RFMP LiPA
Agreement Codon 180 Codon 204 Mutation Codon 180 Codon 204 Mutation Samples, n (%)
Concordant L I mt L I mt 7 (11.7)
M I mt M I mt 2 (3.3)
L,M I mt L,M I mt 2 (3.3)
L I,M mt+wt L I,M mt+wt 2 (3.3)
M,L I,M mt+wt M,L I,M mt+wt 3 (5.0)
M V mt M V mt 7 (11.7)
M,L V,M mt+wt M,L V,M mt+wt 2 (3.3)
M I,V mt M I,V mt 2 (3.3)
L,M I,V mt L,M I,V mt 8 (13.4)
M I,V,M mt+wt M I,V,M mt+wt 2 (3.3)
L,M I,V,M mt+wt L,M I,V,M mt+wt 5 (8.3)
L M wt L M wt 14 (23.3)
Disconcordant L M,I wt+mt L M wt 2 (3.3)
L,M M,V wt+mt L M wt 1 (1.7)
M,L M,V,I wt+mt M,L M,V wt+mt 1 (1.7)
Total 60 (100)
Differing results are underlined. wt, wild-type; mt, mutant type.
with clearance of original YMDD mutations during
prolonged lamivudine therapy [14,27,28]. In addition,
those assays may have been done at relatively early
stages of viral breakthrough when mutant viruses
represent an insufficient fraction of the total viral popu-
lation to be detectable, although this is not highly prob-
able considering the sensitivity of the assays adopted. It
would be worthwhile investigating genotypes at viral
breakthrough on lamivudine therapy, since patients
with YMDD variants may not represent cases with
typical resistance to lamivudine. Further study of the
stratification of viral resistance based on viral geno-
types should explain the significance of this phenom-
enon and provide prognostic markers to determine
variance in the clinical outcome of antiviral therapy.
Previous reports suggest that genotypic succession of
mutations of the HBV polymerase is associated with
early-stage viral acquisition of resistance and occurr-
ence of long-term resistance to lamivudine [29,30].
Moreover, compensatory mutations such as rtL180M,
rtT128N, rtW153Q or G1896A, found in the B subdo-
main of HBV polymerase overlapping surface reading
frame or precore region, have been frequently found in
conjunction with YMDD mutations in patients and
give restored or enhanced replication fitness to YMDD
variant viruses [13,30–32]. The RFMP genotyping
assay is easily adaptable for the detection of other
mutations or polymorphisms and can process 384
samples in one assay set-up. Thus, it could be very
useful to study possible routes of genotypic change to a
more stable and high-level resistance, which might take
place dynamically with the selection and accumulation
of mutants during long-term lamivudine treatment.
When mutations associated with resistance to other
antiviral agents are identified, the RFMP assay can
easily be applied to detect these new mutations.
Hybridization-based assays such as LiPA, as well as
RFMP, appear to be accurate and capable of
contributing to the understanding of the occurrence
of HBV mutants, but can only be used for the identi-
fication of known mutants. A crucial problem is the
detection of emerging novel mutants. Recently,
Niesters et al. and Bozdayi et al. reported detection of
novel YMDD variants (rtM204S) during lamivudine
treatment [15,33]. Since the RFMP assay uses the
principle of identifying the genotype by reading the
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Figure 3. Comparison of RFMP and LiPA assays for detecting minor level of mutant virus with a defined mixture of rtM204 and
rtV204 DNA
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RFMP and LiPA results from mixed populations of wild-type rtM204 and mutant plasmids are shown. The wild-type plasmids, equivalent to 104 copies/ml of HBV,
were mixed with the mutant plasmid to make 25, 10, 4, 1 and 0% of mutant versus wild-type DNA mixtures (strips or spectra numbers 1–5 in order). Only the mass
spectra of the 13-mer fragments are shown. Mass peaks and hybridization bands corresponding to rtV204 are indicated by values with an underline and by the
arrow, respectively. amp., amplification; conj., conjugate; m/z, mass-to-charge ratio; RI, relative peak intensity.
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mass composed of three bases in codon 204, it could
detect unidentified variations as well as rtM204I and
rtM204V. Though it has the drawback of not
differentiating between two genotypes with the first
base in common and with the second and third base
having a different order (like ATG and AGT), we
expect this problem can be resolved by repeating the
strategy on the reverse strand, leading to the determi-
nation of the identity of the third base and, subse-
quently, the middle base. 
The RFMP assay is able to screen for known viral
mutants and to identify and characterize previously
unidentified mutants in a sensitive, specific and robust
high-throughput manner by combining the merits of
its unique assay chemistry and the mature nature of
MALDI-TOF MS, which is capable of running 384
samples simultaneously with high speed automatic
data acquisition. In terms of cost-effectiveness, the
RFMP assay is comparable with the LiPA assay, at
approximately US $100 per test for reagents and
labour. This cost does not cover the outlay for capital
equipment, which is substantially greater for the
RFMP method. However, in many specialty or refer-
ence laboratories already using mass spectrometers for
prenatal metabolite screening or for single nucleotide
polymorphism genotyping, the capital cost would be
reduced because this equipment can also be used for
the RFMP assay.
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